Great Grexit! Dan That Man
Plus: Natcore's Cell A Big Buy | GSV | BBSI | Personal Shtuff
?
thomcalandra.com?
LOS ANGELES -- ?TCR FAMILY, what is to say here? This again from
Daniel Carlson. He called for a broad
stock market decline, and
TCR family got it first Monday morning.
?See below for Daniel's addition Tuesday to the stock market's death rattle.? This is actionable, TCR family.
Briefly:Natcore's technology breakthrough today is significant. It's a first in the making of solar back-contact cells using lasers. The stock is reaching toward the sun today. (NXT in Canada and NXCTF in USA)
See NXT news.
Gold Standard Ventures raises money at market and dilutes its current shareholders. I hold the shares of our Nevada gold-silver developer. I told CEO
Jonathan Awde, "Yuck!" Direct quote. I mean, another 19 million-plus shares (with Macquarie over-allotment) added to the current 124 million shares? His response late Monday, after news of the public share offering at market prices came across zee wire: "Our biggest shareholder's taking a huge chinck, that's yuck?" This might be so, according to Jonathan Awde in Vancouver, Canada. Still, why does
the GSV press releasenot state it? I believe Canada's
Albert Friedberg is the largest GSV shareholder --
Gold Standard Ventures. As I said, I hold, understanding how dilution is to be expected in gold project developers -- but so often, and so damaging to stock price?
Personal Shtuff: Looking for a USA gold mine that is privately held, in a friendly permitting jurisdiction and, well, if you have something you are not sharing with others, ping-eth me. ... Gemma Bean, 15, reports fromAurillac, France -- "The police say they found the stolen suitcase, but they aren't saying if there is anything in it! Stay tuned, TCR family. Confirmation of that from The Bean ?requires a three-hour drive from the Aurillac foothills back to the train station where the drama began. ...Cambodia Fully Charmed Tour -- Six Days & Counting: Angkor Gold -- Prepare For What Could Be A Positively Shocking [And Positive] ANK Stock ?development
-- Thom Calandra at thomcalandra.com?
?
?DANIEL CARLSON ON TUESDAY:
I believe we go lower for all the reasons I outlined MONDAY?.
?
Sure, the US is the best place to be and money is coming here. However, US equity fund outflows have started and that will dwarf the money coming into US stocks from abroad; ?most safe haven money goes into short term treasuries. I saw an interesting chart recently that showed great correlation between margin debt and market tops; margin debt is at an all time high.
The markets really need to price in a Grexit and the possible death of the Euro that would follow. Greece will default. It’s what happens afterwards that is the biggest question mark.
Grexit = Greek exit from Euroland.?
I think the equally good if not better call will be this
BBSI.
Barrett Business Solutions reports on February 4
th and I think business is strong and the shorts will get squeezed. [
Thom:I point out the latest stat is that short-sellers control about 13% of BBSI. Dan Our Man In Fairfax also says gold will show sharp gains once the dollar cools its heels.]?
-- ?
Daniel Carlson?, Fairfax, California
?
R?eport Via TCR?: Author sees 10% death rattle for big stocks
The next segment was originally published at market open Monday January 26, 2014
FAIRFAX, California -- A member of our
TCR family is getting some editorial
l-o-v-e for his market analysis.
?
Daniel Carlson, who lives just up the road here in Marin County, California, sees a 10 percent decline ahead for North America's biggest stocks. Mr. Carlson's latest is here:
see article.
Dan is chief financial officer of
American Sands Energy (AMSE) -- alternative oil in Utah. His article is concise: poor earnings, possible deflation worldwide are a death rattle for what appear to be expensive equities right now. [I own AMSE shares.]
DC is not all d
owner. He sends equity
love the way of Barrett Business Solutions in
this article. Barrett's earnings report is expected by February 4.
Fast Tracking: In our
TCR corner of the investment gallery,
BioCryst Pharmaceutical today says it received a follow-on "fast track" status for its
hereditary angioedema treatment. The U.S. Food & Drug Administration's fast track follows a European "orphan" drug branding for the compound, called BCX4161. See BCRX
press release.
The drug candidate also received
orphan status from the FDA in the USA. Click on the links to discover what the regulatory terms mean - they are both positives for the drug developer. {BioCryst also is developing compounds for possible treatment of Ebola and leukemia, and it received December approval in the USA for its RapiVab influenza treatment.]
BioCryst at the start of this final January week is the only equity with some forward motion on our
TCR screens. A
Business Journal writer does a very good job summarizing the BioCryst development. He is in the (North Carolina) Research Triangle where BioCryst has its HQ.
?I added to my BCRX holdings on Friday at $10.97. I own about 22,500 shares.?
Portugal: I expect
Colt Resources (GTP in Canada) to mark some paragraphs this week. Likely we will see a press release on the future of at least one of its two Portugal projects: gold and tungsten. Colt also has one toe in a Pakistan copper-gold project.
Las Vegas
Show In April: In case you missed the review -- I probably will be in attendance at
Growth Capital Expo, where I am assured there will be excellent coffee and gourmand, if not gourmet, level food offerings.
See more.
HAPPY BIRTHDAY: TCR FAMILY member
Leonie Jopp celebrates here 16th today. She's on her way back to her Germany village in one week from a six-month USA stay. ... Her pal, our own
Gemma, got to Paris on Friday and then suffered the teen-shock of having her lone piece of luggage extracted from her train to the French village of Aurillac, where she will be studying the next few months. Oh well, thieves are everywhere, I suppose. At least, Gemma Bean held onto her Kindle and her brand-new iPhone 6. Who needs clothes and beanies, anyway?
?-- Thom Calandra?
THE CALANDRA REPORT: Subscribe
Now $139 yearly!
See: a thomcalandra.com home for our expanding TCR family.
THE CALANDRA REPORT
$139: Will Recur Yearly
Thom Calandra & TCR are researchers and investors. They are not registered investment advisers. The research and material they offer to subscribers are meant as editorial opinion.